FDA extends Exelixis cancer drug review by three months, cutting value 2.35%
AI Summary- FDA extended its review of Exelixis' zanzalintinib by three months.
- 2.35%: The delay reduced zanzalintinib's present value.
- FDA revealed no new clinical failures or safety concerns.